MedElevator Войти в исследования
← Поиск публикаций
Cancer cell · 2026

Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Hu Mengying, Liu Di-Ao, Wortzel Inbal, Collier Paul, Nelson Theodore M, Foox Jonathan, Zhong Guojie, Tobias Gabriel, Asao Tetsuhiko, Bojmar Linda, Kenific Candia M, Wang Gang, Caielli Simone, Wan Zurong, Qureshy Sarah, Reed Max, Piszczatowski Richard, Ravisankar Purnima, Brown Julia A, Xiong Sihan, Wang Huajuan, Lauritzen Pernille, Aylon Yael, Molina Henrik, Jarnagin William R, Oren Moshe, Stanger Ben Z, Bui Jack, Bergers Gabriele, Noël Agnès, Grandgenett Paul M, Hollingsworth Michael A, Tuveson David, Boudreau Nancy, Bromberg Jacqueline, Kelsen David, Jones David R, Santambrogio Laura, Zeng Melody Y, Pascual Virginia, Kim Han Sang, Mason Christopher E, Zhang Haiying, Matei Irina R, Lyden David

Аннотация

Antigen processing and presentation (APP) is essential for adaptive immunosurveillance. We uncover a mechanism whereby activated T cell-derived extracellular vesicles (ATEVs) drive a positive feedback loop that enhances antigen presentation and immune responses in normal physiology and cancer. ATEV-induced immunogenicity relies on extracellular vesicular double-stranded DNA (EVDNA), which is notably abundant and primarily composed of genomic DNA enriched in immune-related genes, including those encoding APP machinery. Mechanistically, granzyme B (Gzmb) packaged by ATEVs disrupts the nuclear envelope of recipient cells, facilitating intranuclear transfer and subsequent transient expression of EVDNA encoding APP genes. DNase treatment removes most AT-EVDNA, abrogating APP upregulation and thus T cell activation and recruitment to tumors. Notably, ATEVs hold promise as an acellular immunotherapy, restoring APP and synergizing with checkpoint blockade in immunotherapy-refractory tumors. Collectively, our findings uncover a mechanism of transient, non-viral gene delivery by ATEVs that boosts APP and anti-tumor immunity while limiting autoimmunity.

Предметные рубрики MeSH